---
id: posterior-reversible-encephalopathy-syndrome
condition: Posterior Reversible Encephalopathy Syndrome
aliases: [PRES, reversible posterior leukoencephalopathy, RPLS, hypertensive encephalopathy]
icd10: [G93.49]
esi: 2
time_to_harm:
  irreversible_injury: "< 24 hours"
  death: "< 48 hours"
  optimal_intervention_window: "< 6 hours"
category: neurological
track: tier1
sources:
  - type: guideline
    ref: "Fugate JE, Rabinstein AA. Posterior Reversible Encephalopathy Syndrome: Clinical and Radiological Manifestations, Pathophysiology, and Outstanding Questions. Lancet Neurol. 2015;14(9):914-925"
  - type: guideline
    ref: "Hinduja A. Posterior Reversible Encephalopathy Syndrome: Clinical Features and Outcome. Front Neurol. 2020;11:71"
  - type: guideline
    ref: "Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017;264(8):1608-1616"
last_updated: "2026-03-01"
compiled_by: agent
risk_tier: A
validation:
  automated_consistency_check: null
  dose_range_validator: null
  unit_normalization_check: null
  cross_file_consistency_check: null
  citation_presence_check: null
  duplicate_content_check: null
  outlier_detection_flag: clear
  schema_version: "2.0"
  provenance_links: []
---
# Posterior Reversible Encephalopathy Syndrome (PRES)

## Recognition

**Classic presentation:**
- Headache (severe, progressive)
- Seizures (60-75%): generalized tonic-clonic most common; can be presenting feature
- Visual disturbances (50-67%): cortical blindness, hemianopia, blurred vision, visual neglect
- Altered mental status: confusion, agitation, somnolence, coma
- Acute hypertension: SBP often 160-250 mmHg (but PRES can occur at "normal" pressures in eclampsia or immunosuppression)

**Common precipitants:**
- Hypertensive emergency (most common)
- Eclampsia/preeclampsia
- Immunosuppressive/cytotoxic drugs: cyclosporine, tacrolimus, cisplatin, bevacizumab
- Renal failure (acute or chronic)
- Autoimmune disease (lupus, scleroderma)
- Sepsis/shock
- Blood transfusion, IV immunoglobulin

**MRI findings (diagnostic):**
- Bilateral, symmetric vasogenic edema predominantly in parieto-occipital white matter
- T2/FLAIR hyperintensity in posterior circulation territories
- Atypical patterns: frontal, brainstem, or basal ganglia involvement in 20-30%
- DWI: typically shows facilitated diffusion (vasogenic, not cytotoxic); restricted diffusion suggests irreversible injury

## Critical Actions

1. **Immediate BP reduction** — target 20-25% MAP reduction in first 1-2 hours; target MAP 105-125 mmHg
2. **Nicardipine** 5 mg/hr IV, titrate by 2.5 mg/hr q5-15min (max 15 mg/hr) — preferred; OR **clevidipine** 1-2 mg/hr IV, titrate q90sec (max 32 mg/hr)
3. **Seizure control** — lorazepam 4 mg IV for active seizures; magnesium sulfate 4-6 g IV over 15-20 min if eclampsia
4. **Remove offending agent** — discontinue or reduce cyclosporine, tacrolimus, bevacizumab
5. **MRI brain** — confirmatory imaging; CT may appear normal or show subtle hypodensity
6. **Delivery** if eclampsia/preeclampsia (definitive treatment)

## Differential Diagnosis

- Hypertensive encephalopathy without PRES (clinical overlap; MRI differentiates)
- Acute ischemic stroke (DWI restriction in arterial territory)
- Cerebral venous thrombosis (venous territory infarction; CTV/MRV diagnostic)
- CNS vasculitis (multifocal ischemic lesions; vessel wall imaging)
- Acute disseminated encephalomyelitis (ADEM) (post-infectious; multifocal demyelination)
- Encephalitis (viral or autoimmune; fever, CSF pleocytosis)
- Status epilepticus with postictal imaging changes (often reversible; clinical context)
- Osmotic demyelination syndrome (central pontine myelinolysis; history of rapid sodium correction)

## Workup

- **MRI brain with DWI, FLAIR, T2** — gold standard; demonstrates posterior-predominant vasogenic edema
- **CT head** — initial screening; may show subtle hypodensity but is often normal
- **BMP:** creatinine, electrolytes (renal failure precipitant)
- **CBC with differential, LDH, haptoglobin, peripheral smear** — TMA screen (HUS/TTP)
- **Urinalysis, urine protein** — preeclampsia screen
- **Drug levels:** cyclosporine, tacrolimus trough if applicable
- **Liver function tests** (HELLP syndrome screen)
- **LP** — only if meningitis/encephalitis on differential; PRES CSF is typically normal or mildly elevated protein

## Treatment

### Blood Pressure Management
- **Nicardipine** 5 mg/hr IV, titrate by 2.5 mg/hr q5-15min (max 15 mg/hr) — first-line
- **Clevidipine** 1-2 mg/hr IV, titrate q90sec (max 32 mg/hr) — alternative
- **Labetalol** 20 mg IV bolus, then 0.5-2 mg/min IV infusion — avoid in eclampsia (some prefer for non-eclamptic PRES)
- **Target:** reduce MAP by 20-25% in first 1-2 hours; avoid precipitous drops
- **Avoid:** nitroprusside (increases ICP), hydralazine (unpredictable)

### Eclampsia-Specific
- **Magnesium sulfate** 4-6 g IV over 15-20 min, then 1-2 g/hr IV infusion (target Mg 4-7 mEq/L)
- Magnesium is first-line for both seizure treatment and prophylaxis in eclampsia
- Expedite delivery — definitive treatment

### Seizure Management (Non-Eclamptic)
- **Lorazepam** 4 mg IV for active seizures, may repeat q5-10min
- **Levetiracetam** 1000-1500 mg IV for seizure prophylaxis/second-line
- Short-term AED only; seizures resolve with PRES treatment
- Avoid phenytoin (enzyme induction, less effective in PRES)

### Immunosuppressant-Related
- Discontinue or dose-reduce offending agent
- Switch calcineurin inhibitor class (cyclosporine to tacrolimus or vice versa) under transplant team guidance
- Discontinue bevacizumab, cisplatin

## Disposition

- **Active seizures, altered mental status, severe hypertension:** ICU admission
- **Eclampsia:** labor and delivery with ICU-level monitoring
- **Stable PRES with controlled BP and no seizures:** step-down or telemetry unit
- **Discharge:** only after MRI-confirmed improvement, BP controlled on oral regimen, no recurrent seizures; close neurology follow-up

## Pitfalls

1. **Assuming PRES requires hypertension.** PRES occurs at normal blood pressures in eclampsia, immunosuppression, and autoimmune disease. The pathophysiology involves endothelial dysfunction, not solely hypertension.

2. **Relying on CT alone for diagnosis.** CT is normal in up to 50% of PRES cases. MRI with FLAIR and DWI is required. Do not exclude the diagnosis based on a normal CT.

3. **Overcorrecting blood pressure.** Precipitous BP reduction can cause watershed ischemia. Reduce MAP by 20-25% in the first 1-2 hours, not to normal.

4. **Missing irreversible injury.** "Reversible" is a misnomer in 10-25% of cases. DWI restriction (cytotoxic edema) on MRI indicates irreversible infarction, not vasogenic edema. These patients have worse outcomes.

5. **Not recognizing atypical distributions.** PRES does not always involve the posterior circulation. Frontal lobe, brainstem, basal ganglia, and even spinal cord involvement are reported. Do not exclude PRES based on imaging distribution alone.

6. **Giving phenytoin for eclamptic seizures instead of magnesium.** Magnesium sulfate is superior to phenytoin for both treatment and prevention of eclamptic seizures (MAGPIE trial). Phenytoin should not be used as first-line.
